Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction

Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction Publisher

Tavakoliardakani M¹ ; Haghighi S² ; Shokouhi S³ ; Abtahinaeini B⁴ ; Meidani M⁵ ; Hassanpour R¹ ; Saffaei A⁶

Show Affiliations

1. Department of Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Department of Hematology and Oncology, Ayatollah Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Department of Infectious Diseases & Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4. Skin diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
5. Department of Infectious Diseases, Isfahan University of Medical Sciences, Isfahan, Iran
6. Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Eurasian Journal of Medicine Published:2019

Abstract

Palmoplantar Erythrodysesthesia Syndrome (PPES) caused by chemotherapeutic agents is rarely life threatening and requires a reduction in dose or discontinuation of chemotherapy. The use of cytarabine and doxorubicin in the treatment of acute myeloid leukemia (AML) along with voriconazole can potentially alter the metabolism of the drugs and cause some interactions. In this study, we presented a case of AML who received cytarabine and doxorubicin as a chemotherapy regimen and voriconazole as a prophylactic anti-fungalIn this combination, voriconazole probably inhibits the P-glycoprotein pump, which leads to an increase in the cytarabine concentration. The emphasis of this report is the awareness of clinicians and pharmacotherapists about these interactions. © 2019, AVES. All rights reserved.

Experts (# of related papers)

View all Related Experts

Adel Tabesh (1)

Leila Sadeghalbanaei (1)

Style	Citing Format
MLA	Tavakoliardakani M, et al.. "Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction." Eurasian Journal of Medicine, vol. 51, no. 3, 2019, pp. 313-315.
APA	Tavakoliardakani M, Haghighi S, Shokouhi S, Abtahinaeini B, Meidani M, Hassanpour R, Saffaei A (2019). Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction. Eurasian Journal of Medicine, 51(3), 313-315.
Chicago	Tavakoliardakani M, Haghighi S, Shokouhi S, Abtahinaeini B, Meidani M, Hassanpour R, Saffaei A. "Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction." Eurasian Journal of Medicine 51, no. 3 (2019): 313-315.
Harvard	Tavakoliardakani M et al. (2019) 'Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction', Eurasian Journal of Medicine, 51(3), pp. 313-315.
Vancouver	Tavakoliardakani M, Haghighi S, Shokouhi S, Abtahinaeini B, Meidani M, Hassanpour R, et al.. Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction. Eurasian Journal of Medicine. 2019;51(3):313-315.
BibTex	@article{ author = {Tavakoliardakani M and Haghighi S and Shokouhi S and Abtahinaeini B and Meidani M and Hassanpour R and Saffaei A}, title = {Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction}, journal = {Eurasian Journal of Medicine}, volume = {51}, number = {3}, pages = {313-315}, year = {2019} }
RIS	TY - JOUR AU - Tavakoliardakani M AU - Haghighi S AU - Shokouhi S AU - Abtahinaeini B AU - Meidani M AU - Hassanpour R AU - Saffaei A TI - Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction JO - Eurasian Journal of Medicine VL - 51 IS - 3 SP - 313 EP - 315 PY - 2019 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract